The importance of beta blockers in the treatment of heart failure
Heart failure, the only cardiovascular disease with an increasing incidence, is associated with significant mortality and poses a considerable economic burden. Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large ran...
Gespeichert in:
| Veröffentlicht in: | American family physician 2000-12, Vol.62 (11), p.2453-2462 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2462 |
|---|---|
| container_issue | 11 |
| container_start_page | 2453 |
| container_title | American family physician |
| container_volume | 62 |
| creator | Chavey, 2nd, W E |
| description | Heart failure, the only cardiovascular disease with an increasing incidence, is associated with significant mortality and poses a considerable economic burden. Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of significant improvement in mortality rates in patients with heart failure who were given beta blockers in addition to angiotensin-converting enzyme inhibitors, diuretics and, sometimes, digoxin. Beta blockers should now be considered standard therapy in patients with New York Heart Association class II or class III heart failure who are hemodynamically stable, who do not have dyspnea at rest and who have no other contraindications to the use of these agents. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72508133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>65167407</sourcerecordid><originalsourceid>FETCH-LOGICAL-p234t-2675577978179ede4ec9c1efc8462614a5b0eb7102173dfd9f0537ae239cb0363</originalsourceid><addsrcrecordid>eNpd0L1qwzAUBWANLU2a9BWK6NDNIOnaljWG0D8IdEkhm5HkK-LUtlxJHvr2dWi6dLoc-Dgc7hVZMsZEVkF1WJDbGE9zlAVXN2TBOQcmgC_JZn9E2vajD0kPFql31GDS1HTefmKItB1omkkKqFOPQzqLI-qQqNNtNwVck2unu4h3l7siH89P--1rtnt_edtudtkoIE-ZKGVRSKlkxaXCBnO0ynJ0tspLUfJcF4ahkZwJLqFxjXKsAKlRgLKGQQkr8vjbOwb_NWFMdd9Gi12nB_RTrKUoWMUBZvjwD578FIZ5Wz0vEUrm7IzuL2gyPTb1GNpeh-_67zPwAxoxXHk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>234297403</pqid></control><display><type>article</type><title>The importance of beta blockers in the treatment of heart failure</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chavey, 2nd, W E</creator><creatorcontrib>Chavey, 2nd, W E</creatorcontrib><description>Heart failure, the only cardiovascular disease with an increasing incidence, is associated with significant mortality and poses a considerable economic burden. Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of significant improvement in mortality rates in patients with heart failure who were given beta blockers in addition to angiotensin-converting enzyme inhibitors, diuretics and, sometimes, digoxin. Beta blockers should now be considered standard therapy in patients with New York Heart Association class II or class III heart failure who are hemodynamically stable, who do not have dyspnea at rest and who have no other contraindications to the use of these agents.</description><identifier>ISSN: 0002-838X</identifier><identifier>PMID: 11130231</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Adrenergic beta-Antagonists - administration & dosage ; Adrenergic beta-Antagonists - therapeutic use ; Bisoprolol - therapeutic use ; Carbazoles - therapeutic use ; Clinical trials ; Contraindications ; Drug Administration Schedule ; Drug therapy ; Enzymes ; Female ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - mortality ; Heart Failure - physiopathology ; Humans ; Male ; Metoprolol - therapeutic use ; Mortality ; Patient Selection ; Propanolamines - therapeutic use ; Randomized Controlled Trials as Topic ; Severity of Illness Index</subject><ispartof>American family physician, 2000-12, Vol.62 (11), p.2453-2462</ispartof><rights>Copyright American Academy of Family Physicians Dec 1, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11130231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chavey, 2nd, W E</creatorcontrib><title>The importance of beta blockers in the treatment of heart failure</title><title>American family physician</title><addtitle>Am Fam Physician</addtitle><description>Heart failure, the only cardiovascular disease with an increasing incidence, is associated with significant mortality and poses a considerable economic burden. Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of significant improvement in mortality rates in patients with heart failure who were given beta blockers in addition to angiotensin-converting enzyme inhibitors, diuretics and, sometimes, digoxin. Beta blockers should now be considered standard therapy in patients with New York Heart Association class II or class III heart failure who are hemodynamically stable, who do not have dyspnea at rest and who have no other contraindications to the use of these agents.</description><subject>Adrenergic beta-Antagonists - administration & dosage</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Bisoprolol - therapeutic use</subject><subject>Carbazoles - therapeutic use</subject><subject>Clinical trials</subject><subject>Contraindications</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Enzymes</subject><subject>Female</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Male</subject><subject>Metoprolol - therapeutic use</subject><subject>Mortality</subject><subject>Patient Selection</subject><subject>Propanolamines - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Severity of Illness Index</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0L1qwzAUBWANLU2a9BWK6NDNIOnaljWG0D8IdEkhm5HkK-LUtlxJHvr2dWi6dLoc-Dgc7hVZMsZEVkF1WJDbGE9zlAVXN2TBOQcmgC_JZn9E2vajD0kPFql31GDS1HTefmKItB1omkkKqFOPQzqLI-qQqNNtNwVck2unu4h3l7siH89P--1rtnt_edtudtkoIE-ZKGVRSKlkxaXCBnO0ynJ0tspLUfJcF4ahkZwJLqFxjXKsAKlRgLKGQQkr8vjbOwb_NWFMdd9Gi12nB_RTrKUoWMUBZvjwD578FIZ5Wz0vEUrm7IzuL2gyPTb1GNpeh-_67zPwAxoxXHk</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>Chavey, 2nd, W E</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>The importance of beta blockers in the treatment of heart failure</title><author>Chavey, 2nd, W E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p234t-2675577978179ede4ec9c1efc8462614a5b0eb7102173dfd9f0537ae239cb0363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adrenergic beta-Antagonists - administration & dosage</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Bisoprolol - therapeutic use</topic><topic>Carbazoles - therapeutic use</topic><topic>Clinical trials</topic><topic>Contraindications</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Enzymes</topic><topic>Female</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Male</topic><topic>Metoprolol - therapeutic use</topic><topic>Mortality</topic><topic>Patient Selection</topic><topic>Propanolamines - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chavey, 2nd, W E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chavey, 2nd, W E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The importance of beta blockers in the treatment of heart failure</atitle><jtitle>American family physician</jtitle><addtitle>Am Fam Physician</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>62</volume><issue>11</issue><spage>2453</spage><epage>2462</epage><pages>2453-2462</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>Heart failure, the only cardiovascular disease with an increasing incidence, is associated with significant mortality and poses a considerable economic burden. Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of significant improvement in mortality rates in patients with heart failure who were given beta blockers in addition to angiotensin-converting enzyme inhibitors, diuretics and, sometimes, digoxin. Beta blockers should now be considered standard therapy in patients with New York Heart Association class II or class III heart failure who are hemodynamically stable, who do not have dyspnea at rest and who have no other contraindications to the use of these agents.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>11130231</pmid><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-838X |
| ispartof | American family physician, 2000-12, Vol.62 (11), p.2453-2462 |
| issn | 0002-838X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72508133 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adrenergic beta-Antagonists - administration & dosage Adrenergic beta-Antagonists - therapeutic use Bisoprolol - therapeutic use Carbazoles - therapeutic use Clinical trials Contraindications Drug Administration Schedule Drug therapy Enzymes Female Heart failure Heart Failure - drug therapy Heart Failure - mortality Heart Failure - physiopathology Humans Male Metoprolol - therapeutic use Mortality Patient Selection Propanolamines - therapeutic use Randomized Controlled Trials as Topic Severity of Illness Index |
| title | The importance of beta blockers in the treatment of heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T09%3A17%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20importance%20of%20beta%20blockers%20in%20the%20treatment%20of%20heart%20failure&rft.jtitle=American%20family%20physician&rft.au=Chavey,%202nd,%20W%20E&rft.date=2000-12-01&rft.volume=62&rft.issue=11&rft.spage=2453&rft.epage=2462&rft.pages=2453-2462&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E65167407%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=234297403&rft_id=info:pmid/11130231&rfr_iscdi=true |